Fresenius Medical Care AG & Co. KGaA · FMS · FY2026 Q3 · Calendar Q4 2026
Fresenius Medical Care cuts 2026 outlook as cost and reimbursement pressure persist
Stable Q3 revenue and ongoing product expansion and cost savings provide support, but the lowered 2026 operating-income outlook and rising reimbursement and cost pressures weaken the near-term earnings picture.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about FMS FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter’s maintained guidance and confident tone, management now describes a cautious backdrop and has lowered 2026 operating-income guidance to flat-to-negative mid-single-digit growth. It cited TDAPA reimbursement headwinds and inflationary pressure; it also reported continued U.S. product rollouts and FME25+ savings.
Guidance delta
2026 operating-income guidance was lowered to flat-to-negative mid-single-digit growth. The supplied prior-quarter analysis says guidance had been maintained.
Key takeaways
- Revenue and earnings were broadly stable in Q3 despite TDAPA and inflation pressures.
- The company reported 348 U.S. clinic conversions for HV-HDF and the 5008X CAREsystem, and FME25+ savings of €74 million for the quarter.
- Management lowered its full-year 2026 operating-income outlook; reported EPS and revenue actuals are not available in the supplied event facts.
Management priorities
- Continue U.S. rollout of the 5008X CAREsystem, targeting 20% of the install base by year-end.
- Advance FME25+ savings while balancing cost discipline with investment for growth.
- Develop the 2027 strategic plan and financial assumptions for release in February.
Follow FMS with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationFresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products.…
Healthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RVTY Revvity, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +10.8% | Revvity Raises FY2026 Outlook After 7% Q3 Organic Growth |
| WAT Waters Corporation | FY2026 Q3 · Calendar Q4 2026 | — | +3.8% | Waters Raises FY2026 Revenue Outlook as Organic Growth Accelerates |
| HSIC Henry Schein, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +0.0% | Henry Schein raises 2026 EPS outlook as U.S. dental sales grow |
| PHG Koninklijke Philips N.V. | FY2026 Q3 · Calendar Q4 2026 | — | +4.8% | Philips Q3: order momentum and margins improve; outlook held |
| VRTX Vertex Pharmaceuticals Incorporated | FY2026 Q3 · Calendar Q4 2026 | -1.2% | -1.0% | Vertex lifts 2026 outlook as CF franchise and newer products support growth |
| JAZZ Jazz Pharmaceuticals plc | FY2026 Q3 · Calendar Q4 2026 | +4.2% | -0.7% | Jazz lifts 2026 revenue outlook as Ziihera launch adds momentum |
Latest beats and misses
Who reports nextBeat on EPS
- EQH-PAFY2026 Q3 · November 2, 2026+14.5% EPS— move
- WMBFY2026 Q3 · November 2, 2026+0.2% EPS+3.5% move
- TSEMFY2026 Q3 · November 2, 2026+7.5% EPS-6.7% move
- CLXFY2027 Q1 · November 2, 2026+44.9% EPS+2.2% move
- AAPLFY2026 Q4 · November 2, 2026+3.0% EPS-1.8% move
- PLTRFY2026 Q3 · November 2, 2026+8.3% EPS-3.1% move
Missed on EPS
- CRBGFY2026 Q3 · November 2, 2026-0.8% EPS+2.5% move
- VRTXFY2026 Q3 · November 2, 2026-1.2% EPS-1.0% move
- PEGFY2026 Q3 · November 2, 2026-3.4% EPS+0.1% move
- RYAAYFY2027 Q2 · November 2, 2026-0.3% EPS+2.9% move
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
Get the FMS recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-03T18:09:03.554375+00:00
- FN2 earnings calendar · 2026-11-03T01:23:13.143323+00:00
- Polygon adjusted daily market bars · 2026-11-03T18:30:46.171124+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-03T18:30:46.168503+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.